other pages left banner top

other pages banner

Chartis System Technology

Real-time assessment of lung function.

Endobronchial lung volume reduction therapy can lead to significant clinical benefits3,4 when physicians plan treatment based on the patient’s specific lung anatomy. Collateral Ventilation (CV) can limit the effectiveness of lung volume reduction therapy.1,2 Collateral channels can allow backfill into the target lobe and prevent significant lung volume reduction.

Know Before You Go.

Knowing collateral status of the patient’s target lobes allows physicians to predict and plan outcomes. The Chartis® Pulmonary Assessment System enables intervening physicians to prospectively and accurately plan EBV treatment for their patients to ensure maximal lung volume reduction from this non-surgical, minimally invasive treatment approach.4

Chartis System Features and Benefits:



Techical Platform




Chartis balloon catheter

All-in-One Console:
  • Displays precise measurement of expiratory flow, inspiratory pressure, and collateral resistance
  • Large graphical interface for easy viewing and interpretation
  • Lightweight, compact design
  • Touchscreen eliminates need to sanitize and store keyboards
  • Bright color display facilitates at-a-glance monitoring of assessment trends
Disposable Balloon Catheter:
  • Allows multiple assessments on a single patient
  • Occludes targeted airways to isolate lung compartments during CV assessments
  • Compliant PEBAX balloon conforms to seal a range of airways, including lobar and segmental levels
  • Transparent balloon for easy visualization of placement within the airway
  • Compatible with standard 2.8 mm working channel video bronchoscopes
  • Includes accessories required for balloon inflation and catheter flushing

Chartis System:

  • Accurate assessments in approximately 3 – 5 minutes
  • Report generation for patient medical records
  • Stores over 5,000 patient assessments
  • Data export to USB
  • 3-year calibration cycle

Footnotes

1. Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.

2. Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.

3. Gompelmann D, et al. Predicting Atelectasis by Assessment of Collateral Ventilation prior to Endobronchial Lung Volume Reduction: A Feasibility Study. Respiration (DOI:10.1159/000319441), Published Online: July 21, 2010.

4. Use of Chartis Pulmonary Assessment System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) - Chartis Multi-Centre Study, data presented at ATS2011. Data on file with Pulmonx, Inc.

Normal 0 false false false EN-US X-NONE X-NONE

Know Before You Go.

Zephyr® EBV is an Investigational Device in the United States. Limited by U.S. law to investigational use. Chartis® system is for use/sale outside the U.S. only.

Attention: open in a new window. Print